AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04218162
Drug: Lasmiditan 100mg
RxNorm normalized name: LASMIDITAN 100MG TAB
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lasmiditan 100mg
Trial: NCT01556776
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
Trial: NCT03484832
Drug: EMLA Cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
Trial: NCT02252809
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02252809
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01480609
Drug: Retigabine / Ezogabine
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
Trial: NCT02998047
Drug: Lintuzumab AC 225
RxNorm normalized name: Actinium AC 225 lintuzumab
DrugBank: Lintuzumab (DB14877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
Trial: NCT00777400
Drug: Efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg/kg of efalizumab administered sub q once weekly
Trial: NCT00195247
Drug: TTI-237
RxNorm normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03503292
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapid metabolizer will receive 1mg IV Granisetron
Trial: NCT03503292
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Poor or normal metabolizers will receive 4mg Ondansetron IV
Trial: NCT01540409
Drug: AVI-4658 (Eteplirsen)
RxNorm normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
Trial: NCT01342744
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin(850 mg) 1tab oral twice aday
Trial: NCT00902421
Drug: Selective serotonin reuptake inhibitors
RxNorm normalized name: Selective serotonin reuptake inhibitors
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram 10mg once daily for 3 months
Trial: NCT00103519
Drug: DITPA (3,5-diiodothyropropionic acid)
RxNorm normalized name: DITPA
DrugBank: 3,5-diiodothyropropionic acid (DB12629)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00600041
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
Trial: NCT00462735
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
Trial: NCT00462735
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
Trial: NCT00600691
Drug: Finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet (5mg) of finasteride
Trial: NCT02278614
Drug: T2347
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
Trial: NCT02278614
Drug: Xalacom
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
Trial: NCT03971604
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treated with Vitamin A
Trial: NCT03971604
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treated with Vitamin E
Trial: NCT04058704
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mg Tid/375mg per day
Trial: NCT00525824
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg
Trial: NCT00044824
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01878669
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01878669
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01999218
Drug: Ertugliflozin 5 mg
RxNorm normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
Trial: NCT01999218
Drug: Ertugliflozin 10 mg
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
Trial: NCT01999218
Drug: Glimerpiride
RxNorm normalized name: Glimepiride
DrugBank: Lime (citrus) (DB10635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
Trial: NCT01999218
Drug: Placebo to Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
Trial: NCT01999218
Drug: Placebo to Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
Trial: NCT01999218
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
Trial: NCT01999218
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open label, oral, once daily, rescue medication as required.
Trial: NCT01182974
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gr of paracetamol PO/PZ/PR
Trial: NCT00534508
Drug: Tacrolimus Ointment 0.1%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily, 14 days treatment
Trial: NCT04664530
Drug: esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
Trial: NCT04664530
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The titration process in the control group with saline are the same as those in the treatment group with esketamine.
Trial: NCT01440517
Drug: Tc99m-Maraciclatide
RxNorm normalized name: Maraciclatide Tc-99m
DrugBank: Technetium Tc-99m maraciclatide (DB19144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
Trial: NCT00871923
Drug: Tarceva (Erlotinib hydrochloride)
RxNorm normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth every day beginning Day 1.
Trial: NCT00227318
Drug: ATACAND
RxNorm normalized name: Atacand
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00045747
Drug: 7-hydroxystaurosporine
RxNorm normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539018
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
Trial: NCT01452139
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
Trial: NCT03274427
Drug: Trimetazidine hydrochloride
RxNorm normalized name: Trimetazidine hydrochloride
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
Trial: NCT01463111
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Trial: NCT01463111
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Trial: NCT01463111
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Trial: NCT01336751
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution for subcutaneous injection
Trial: NCT01336751
Drug: 75% insulin lispro protamine suspension and 25 % insulin lispro injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: suspension for subcutaneous injection
Trial: NCT00428220
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib
Trial: NCT02691403
Drug: levo-bupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01863251
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02683070
Drug: Intravenous tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
Trial: NCT04134130
Drug: Degarelix 120 MG [Firmagon]
RxNorm normalized name: degarelix 120 MG [Firmagon]
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two doses of degarelix, 240 mg, subcutaneously once, at study start.
Trial: NCT04134130
Drug: Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose 1000 mg testosterone once, after 3 weeks.
Trial: NCT03209648
Drug: Debio 1450
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 1450, 40 mg capsule.
Trial: NCT03209648
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole, 20 mL of 10 mg/mL solution.
Trial: NCT03824405
Drug: BTX 1204
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: BTX 1204 liquid formulation
Trial: NCT01820455
Drug: Chlorhexidine, Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
Trial: NCT02581397
Drug: Guaiacol suppository
RxNorm normalized name: guaiacol
DrugBank: Guaiacol (DB11359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
Trial: NCT02340182
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg 3dd2
Trial: NCT02340182
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg 2dd1
Trial: NCT02340182
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg 3dd1
Trial: NCT05393414
Drug: Opioid sparing protocol
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
Trial: NCT01231321
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
Trial: NCT01274780
Drug: Darunavir / Ritonavir + Tenofovir / Emtricitabine
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral, 800/100 mg, qd + oral, 300/200 mg, qd
Trial: NCT01274780
Drug: Atazanavir / Ritonavir + Tenofovir / Emtricitabine
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral, 300/100 mg, qd + oral, 300/200 mg, qd
Trial: NCT02254785
Drug: cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
Trial: NCT02254785
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone 1000mg daily (oral) until disease progression
Trial: NCT02254785
Drug: Enzalutamide 160mg daily (oral)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160mg daily (oral) until disease progression
Trial: NCT04646161
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
Trial: NCT01752790
Drug: Step-up
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
Trial: NCT00445848
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02337283
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03040635
Drug: Risdiplam
RxNorm normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral doses of Risdiplam will be administered on Day 1.
Trial: NCT02736266
Drug: Pembrolizumab (MK-3475)
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
Trial: NCT00970814
Drug: Levetiracetam XR
RxNorm normalized name: levetiracetam Extended Release Oral Tablet
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg - 2000mg Once per day 16 weeks
Trial: NCT00970814
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg - 2000mg Once per day 16 weeks
Trial: NCT00219882
Drug: standardized turmeric root extract
RxNorm normalized name: turmeric root extract
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
Trial: NCT04710407
Drug: TBPM-PI-HBr
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
Trial: NCT00993109
Drug: Adalat (Nifedipine, BAYA1040)
RxNorm normalized name: nifedipine 20 MG [Adalat]
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
Trial: NCT00993109
Drug: Diovan (Valsartan)
RxNorm normalized name: valsartan Oral Tablet [Diovan]
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 160 mg OM (Two Valsartan 80mg tablets)
Trial: NCT01991223
Drug: NS infusion
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be infused during surgery
Trial: NCT00481325
Drug: pexacerfont
RxNorm normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
Trial: NCT00481325
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
Trial: NCT00970450
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g i.v. once
Trial: NCT00970450
Drug: Tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg i.v. once
Trial: NCT01188148
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg per day of memantine
Trial: NCT00800319
Drug: RDC-0313
RxNorm normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given in 5, 15, 25, 50, and 75 mg single doses
Trial: NCT04319289
Drug: Vitamin D supplementation only
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule containing (cholecalciferol 400 IU) was taken every day .
Trial: NCT02480400
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
Trial: NCT03606447
Drug: Uproleselan
RxNorm normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-Uproleselan
Trial: NCT00922883
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no